Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754799 | 0.86 | EPHX1 (0.44) | RORCPGK1 | |
| SCHEMBL10582291 | 0.84 | TTR (0.45) | SLC1A5HCRTR1HCRTR2SCN3ASCN1A | |
| SCHEMBL4493894 | 0.82 | IDO1 (0.52) | SLC1A5HCRTR1HCRTR2SCN3ASCN1A | |
| SCHEMBL169779 | 0.82 | PGK1 (0.44) | SLC1A5HCRTR1HCRTR2RORCPGK1 | |
| SCHEMBL101152 | 0.82 | MEN1 (0.41) | SLC1A5HCRTR1HCRTR2SCN3ASCN1A | |
| SCHEMBL3083420 | 0.82 | NPC1 (0.48) | SLC1A5HCRTR1HCRTR2SCN3ASCN1A | |
| SCHEMBL3118077 | 0.82 | CSNK2A1 (0.56) | SLC1A5HCRTR1HCRTR2SCN3ASCN1A | |
| SCHEMBL25182236 | 0.80 | EPHX2 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL12093360 | 0.79 | HCRTR1 (0.43) | SLC1A5HCRTR1HCRTR2SCN3ASCN1A | |
| SCHEMBL18249186 | 0.79 | TAAR1 (0.55) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | SLC1A5 1976/4885HCRTR1 4185/4885HCRTR2 4324/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | SLC1A5 1402/4885HCRTR1 3208/4885HCRTR2 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.